ARS Pharmaceuticals, Inc. SPRY Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from ARS Pharmaceuticals, Inc.’s reported figures.
Based on trailing twelve months.
The official record: ARS Pharmaceuticals, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about ARS Pharmaceuticals, Inc.'s return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ARS Pharmaceuticals, Inc.'s return on equity?
- ARS Pharmaceuticals, Inc. (SPRY) reported return on equity of -136.4% in Q1 2026.
- How has ARS Pharmaceuticals, Inc.'s return on equity changed year-over-year?
- ARS Pharmaceuticals, Inc.'s return on equity decreased by 1873.4% year-over-year, from -6.9% to -136.4%.
- What is the long-term trend for ARS Pharmaceuticals, Inc.'s return on equity?
- Over 2 years (2023 to 2025), ARS Pharmaceuticals, Inc.'s return on equity has grown at a 106.8% compound annual growth rate (CAGR), from -21.6% to -92.3%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.